SCHEMBL4122365

SCHEMBL4122365

CC(C)CCCN(C)CCCC(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
CHRM2 P08172 1/20 0.39
PIK3CD O00329 1/20 0.39
CA12 O43570 1/20 0.35
CA2 P00918 1/20 0.35
CA3 P07451 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CA5B Q9Y2D0 1/20 0.35
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
KDM4C Q9H3R0 2/20 0.32
KDM4A O75164 1/20 0.32
PHF8 Q9UPP1 1/20 0.32
KDM2A Q9Y2K7 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29580790 0.97 LMNA (0.41) LMNACHRM2PIK3CDCA12CA2
SCHEMBL29580455 0.97 LMNA (0.41) LMNACHRM2PIK3CDCA12CA2
SCHEMBL12039802 0.94 LMNA (0.39) LMNACHRM2PIK3CDCA12CA2
SCHEMBL8405817 0.94 CHRM2 (0.48) LMNACHRM2PIK3CDCA12CA2
SCHEMBL26406570 0.92 CHRM2 (0.46) LMNACHRM2PIK3CDALDH1A1KDM4C
SCHEMBL5949010 0.91 LMNA (0.48) LMNACHRM2PIK3CDCA12CA2
SCHEMBL23934075 0.89 ALDH1A1 (0.41) LMNACHRM2PIK3CDCA12CA2
SCHEMBL10081590 0.89 PIK3CD (0.48) LMNACHRM2PIK3CDCA12CA2
SCHEMBL21117163 0.89 LMNA (0.36) LMNACHRM2PIK3CDCA12CA2
SCHEMBL9945708 0.89 GGPS1 (0.38) LMNACHRM2KDM4CKDM4APHF8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067642-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-02-29 US disclosed
US-20230331722-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-10-19 US disclosed
US-11767330-B2 Citrate salt, pharmaceutical compositions, and methods of making and using the same FOGHORN THERAPEUTICS INC. (US) 2023-09-26 US disclosed
US-11696959-B2 Nanoparticle-cell construct with platinum anti-cancer agent CITY OF HOPE (US) 2023-07-11 US disclosed
US-20230142883-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-20190022246-A1 SILICON NANOPARTICLE WITH PLATINUM ANTI-CANCER AGENT CITY OF HOPE 2019-01-24 US disclosed
US-20090093468-A1 Peptide Deformylase Inhibitors ARPIDA A/S (DK) 2009-04-09 US disclosed
US-20070066672-A1 Benzimidazole derivatives and use thereof as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-03-22 US disclosed
EP-1732907-A1 PEPTIDE DEFORMYLASE INHIBITORS Arpida A/S (DK) 2006-12-20 EP disclosed
US-7101940-B2 Chemical compound, method for the production thereof and its use in catalyst systems for producing polyolefins BASELL POLYOLEFINE GMBH (DE) 2006-09-05 US disclosed
EP-1677785-A1 BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS PEPTIDE DEFORMYLASE INHIBITORS Arpida A/S (DK) 2006-07-12 EP disclosed
US-7034173-B2 Chemical products suited for use as co-catalysts, method for the preparation thereof and their use in catalyst systems for producing polyolefins BASELL POLYOLEFINE GMBH (DE) 2006-04-25 US disclosed
US-6953829-B2 Catalyst system and the use thereof BASELL POLYOLEFINE GMBH (DE) 2005-10-11 US disclosed
WO-2005092872-A1 PEPTIDE DEFORMYLASE INHIBITORS ARPIDA A/S (DK) 2005-10-06 WO disclosed
WO-2005037272-A1 BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS PEPTIDE DEFORMYLASE INHIBITORS ARPIDA A/S (DK) 2005-04-28 WO disclosed
US-20030144434-A1 Chemical products suited for use as co-catalysts, method for the preparation thereof and their use in catalyst systems for producing polyolefins EQUISTAR CHEMICALS, LP 2003-07-31 US disclosed
US-20030013913-A1 Chemical compound, method for the production thereof and its use in catalyst systems for producing polyolefins EQUISTAR CHEMICALS, LP 2003-01-16 US disclosed
EP-0625507-B1 Urea derivatives and their use as acat inhibitors NISSHIN FLOUR MILLING CO (JP) 1997-07-23 EP disclosed
US-5621010-A ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS NISSHIN FLOUR MILLING CO., LTD. (JP) 1997-04-15 US disclosed
EP-0625507-A2 Urea derivatives and their use as acat inhibitors NISSHIN FLOUR MILLING CO., LTD. (JP) 1994-11-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190022246-A1 SILICON NANOPARTICLE WITH PLATINUM ANTI-CANCER AGENT POLI, TP53, TOP2A LMNA 2541/4885CHRM2 4879/4885PIK3CD 522/4885
US-11696959-B2 Nanoparticle-cell construct with platinum anti-cancer agent CD47, TP53, CD63 LMNA 2866/4885CHRM2 4869/4885PIK3CD 1242/4885
US-20230331722-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 LMNA 172/4885CHRM2 4878/4885PIK3CD 1598/4885
US-20070066672-A1 Benzimidazole derivatives and use thereof as peptide deformylase inhibitors PDF, MRPL21, PEPD LMNA 1563/4885CHRM2 4409/4885PIK3CD 2215/4885
US-20030144434-A1 Chemical products suited for use as co-catalysts, method for the preparation thereof and their use in catalyst systems for producing polyolefins CBR1, COX6C, CBR3 LMNA 1090/4885CHRM2 329/4885PIK3CD 3242/4885
US-20230142883-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 LMNA 172/4885CHRM2 4878/4885PIK3CD 1598/4885
US-11767330-B2 Citrate salt, pharmaceutical compositions, and methods of making and using the same CS, SMARCC2, SMARCC1 LMNA 1765/4885CHRM2 4348/4885PIK3CD 37/4885
US-20090093468-A1 Peptide Deformylase Inhibitors PDF, PEPD, MRPL21 LMNA 2707/4885CHRM2 4607/4885PIK3CD 3654/4885
US-20030013913-A1 Chemical compound, method for the production thereof and its use in catalyst systems for producing polyolefins SCO2, CNOT1, CYC1 LMNA 3058/4885CHRM2 1348/4885PIK3CD 1777/4885
US-20240067642-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 LMNA 172/4885CHRM2 4878/4885PIK3CD 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.